首页> 外文期刊>Breast cancer >Taste alterations in patients with breast cancer following chemotherapy: a cohort study
【24h】

Taste alterations in patients with breast cancer following chemotherapy: a cohort study

机译:化疗后乳腺癌患者的味道改变:队列研究

获取原文
           

摘要

Background Chemotherapy-induced taste and smell alterations in cancer patients are associated with multiple adverse effects, namely, malnutrition, weight loss, and a diminished quality of life. The aim of this prospective study was to identify the incidence of taste alterations following epirubicin and cyclophosphamide (EC) chemotherapy in patients with breast cancer without previous history of cancer or chemotherapy. Methods Forty-one patients undergoing EC chemotherapy for breast cancer at Tokai University Hospital were included. A subjective (questionnaire) and an objective (filter paper disk method) assessment for 5 basic tastes were administered on day 4 post-chemotherapy and immediately before the subsequent cycle of chemotherapy for each cycle, in addition to an olfactory evaluation and oral examination. The correlation between subjective and objective taste alterations and factors influencing these alterations were analyzed by statistical means. Results The mean incidence of subjective taste alteration on the 4th day after chemotherapy was 53%. In each of the 4 cycles, taste alterations decreased to about 9.0% immediately before the next cycle. A significant correlation between subjective and objective assessments was seen only for salty taste, suggesting important differences in subjective versus objective assessment outcomes. A multivariate analysis indicated that age and body surface area influenced taste alterations. Conclusions EC chemotherapy induced taste alterations in more than 50% of patients, which decreased to less than 10% immediately before the next chemotherapy cycle. A combination of objective and subjective assessments is essential to evaluate taste alterations induced by EC chemotherapy. These could be used in routine clinical practice.
机译:背景技术癌症患者的化疗诱导的味道和嗅觉改变与多重不良反应,即营养不良,减肥和减少的生活质量有关。该前瞻性研究的目的是鉴定因患乳腺癌患者的Epirubic蛋白和环磷酰胺(EC)化疗后的乳腺素和环磷酰胺(EC)化疗的发病率,没有以前的癌症或化疗史。方法包括在托凯大学医院接受乳腺癌患者化疗的四十一名患者。在第4天后,在第4天给予5个基本品味的主观(调查问卷)和目标(滤纸盘方法)评估,并且在随后的每循环的化疗周期之前,除了嗅觉评估和口腔检查之外。通过统计手段分析了影响这些改变的主观和客观味道改变与因素之间的相关性。结果化疗后第4天的主观味道改变的平均发病率为53%。在每个4个循环中的每一个中,在下一个循环之前,味道改变在下一个循环之前立即降至约9.0%。主观和客观评估之间的显着相关性仅用于咸味,表明主观与客观评估结果的重要差异。多变量分析表明年龄和体表面积影响了味道改变。结论EC化疗诱导50%以上的患者的味道改变,在下一个化疗循环之前,在下一次化疗循环之前降至低于10%。目标和主观评估的组合对于评估EC化疗诱导的味道改变至关重要。这些可以用于常规临床实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号